Prurigo nodularis forecast: Light type 2 inflammation with high chances of fibrosis

Curdin Conrad; Christoph Schlapbach

doi:10.1016/j.jaci.2023.11.003

Prurigo nodularis forecast: Light type 2 inflammation with high chances of fibrosis

J Allergy Clin Immunol. 2024 Jan;153(1):93-94. doi: 10.1016/j.jaci.2023.11.003. Epub 2023 Nov 10.

Authors

Curdin Conrad¹, Christoph Schlapbach²

Affiliations

¹ Department of Dermatology, CHUV University Hospital and University of Lausanne, Lausanne, Switzerland.
² Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Electronic address: christoph.schlapbach@insel.ch.

PMID: 37951309
DOI: 10.1016/j.jaci.2023.11.003

No abstract available

Keywords: Prurigo nodularis; T(H)2 cell; atopic dermatitis; dupilumab; fibrosis; inflammation; itch; nemolizumab; pruritus; single-cell RNA sequencing; type 2 inflammation.

Publication types

Editorial
Comment

MeSH terms

Fibrosis
Humans
Inflammation
Prurigo*
Pruritus